# Vertex Pharmaceuticals Incorporated  Share Price Target ‘$465.50’, now 8.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/vertex-pharmaceuticals-incorporated-share-price-target-465.50-now-8.0-upside-potential/4121145310
- Published: 2024-02-29T13:27:55+00:00
- Author: Charlotte Edwards

**Vertex Pharmaceuticals Incorporated** with ticker code (VRTX) have now 24 market
analysts covering the stock. The analyst consensus now points to a rating of ‘buy’.
The range between the high target price and low target price is between $578.00 
and $325.00 calculating the average target share price we see $465.50. (at the time
of writing). Now with the previous closing price of $430.92 and the analysts are
correct then there would likely be a percentage uptick in value of 8.0%. The 50 
day moving average now sits at $422.36 and the 200 day MA is $369.56. The market
capitalization for the company is 110.29B. The stock price is currently at: $426.97
USD

 The potential market cap would be $119,140,177,541 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 30.76, revenue per share of $38.30
and a 13.17% return on assets.

Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company
is focused on developing medicines that treat the underlying cause of cystic fibrosis(
CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell 
disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease,
type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs 
in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO(
elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor
and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company
has a pipeline of investigational small molecule, cell and genetic therapies in 
other serious diseases where it has deep insight into causal human biology, including
sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type
1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.

Share on: